Any life here???
I have a large position in this one, and, with an avg. PT of 23.67 I believe is well justified(no debt, multiple partnerships, new, broad-based MOA, high quality, experienced staff), I have to believe this one continues to function under the radar.
The obvious reason seems to be that their first product involves improved targeting and maximized efficacy for chemo(docetoxil)-therefore, a lot of people must be missing the fact that this technology(acccurins)can be used for all sorts of payloads-this initial chemo product is only a convenient proof of concept.
Wonder when the herd will finally start to take notice and we'll see some volume here(in the stock, as well as on this board-lol!).
Should, as usual, happen quickly...
Regards all,
bw
